Elicera Therapeutics AB (publ) (STO:ELIC)

Market Cap	309.66M +172.3%
Revenue (ttm)	10.86M +52.3%
Net Income	-17.41M
EPS	-0.38
Shares Out	48.54M
PE Ratio	n/a
Forward PE	63.80
Dividend	n/a
Ex-Dividend Date	n/a

Volume	199,607
Average Volume	212,913
Open	6.39
Previous Close	6.38
Day's Range	5.90 - 6.39
52-Week Range	2.10 - 8.43
Beta	0.38
RSI	61.39
Earnings Date	Feb 13, 2026

About Elicera Therapeutics AB

Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 2
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ELIC

Financial Performance

In 2025, Elicera Therapeutics AB's revenue was 10.86 million, an increase of 52.28% compared to the previous year's 7.13 million. Losses were -17.41 million, 8.05% more than in 2024.